Tirzepatide
GIP/GLP-1 Dual Agonist
Tirzepatide (LY3298176) is a synthetic single-molecule peptide that activates two incretin receptors: GIP and GLP-1. It is one of the most extensively studied compounds in metabolic research, with published phase 2 and phase 3 programmes. Supplied strictly for laboratory research use only.
The research profile.
Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide built on a glucose-dependent insulinotropic polypeptide (GIP) backbone, engineered to act as an agonist at both the GIP receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-receptor pharmacology sits between the single GLP-1 agonists described in earlier literature and the triple GIP/GLP-1/glucagon agonists characterised more recently.
The discovery work describes tirzepatide as an imbalanced agonist: its potency at the GIP receptor approaches that of native GIP, while its GLP-1 receptor activity is weaker relative to native GLP-1. A C20 fatty-diacid moiety is conjugated to the peptide backbone, promoting albumin binding and supporting the extended half-life that underpins once-weekly administration in the published trials.
Tirzepatide has one of the largest clinical literatures of any incretin-based compound, spanning phase 2 dose-ranging work, the SURPASS glycaemic-control programme and the SURMOUNT body-weight programme, and it has been approved in several jurisdictions for specific clinical indications. The material supplied here is a lyophilised research compound intended solely for laboratory study of incretin-receptor biology.
17 peer-reviewed studies on Tirzepatide are summarised in our research library, including 9 published since 2023 — with study designs, reported findings and what the evidence does not establish.
Read the Tirzepatide evidence baseFor research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.
Categorised as Metabolic — GLP-1s, lipolytics, and visceral-fat compounds.
The published evidence.
AKH BioLabs does not publish preparation or dosing guidance for this compound class. The peer-reviewed literature below is the definitive reference for study design.
The peer-reviewed publications below characterise Tirzepatide across discovery, pharmacology, and clinical development.
- 01
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab (2018). PubMed · 30473097
- 02
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). PubMed · 34170647
- 03
Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). PubMed · 35658024
- 04
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA (2024). PubMed · 38078870
Independently verified purity.
Every batch is independently tested by the Brown Institute of Biomolecular Research or Janoshik Analytical. The full HPLC and mass-spec report is included in the physical shipment.
- Batch
- 26124
- Test date
- 27 Jul 2026
- Task ID
- #1812420
- Purity
- 99.9%
TR: 30mg | Purity: 99.90%
Verified by Brown Institute of Biomolecular Research. Scan the full report for every measurement.